AHPA continues to follow new COVID-19 regulations, guidance and other government actions. The updates below are the latest guidance and other developments since April 5=19, 2021 to help mitigate the impacts of COVID-19. For earlier COVID-19 regulations and guidance, visit the previous Policy Briefs.

White House to Invest $1.7 Billion to Fight COVID-19 Variants
The Biden Administration is investing $1.7 billion from the American Rescue Plan to help states and jurisdictions be more effective in fighting COVID-19 variant mutations. Measures include expanding genome sequencing, the launch of new genome epidemiology research centers and support for national bioinformatics infrastructure.

Revoked: Emergency Use Authorization for Monoclonal Antibody Bamlanivimab
The FDA has revoked the EUA for Eli Lilly’s bamlanivimab’s use as a single-dose COVID-19 monoclonal antibody therapy due to the increased spread of COVID-19 variants that are resistant to the therapy. Bamlanivimab is still authorized for joint-use with Lilly’s etesevimab to treat mild-to-moderate COVID-19.

View PDF